Aethlon Medical, Inc v. Controller General Of Patents, Designs and Trademarks

Patents are territorial by nature, but the strategies used to win them abroad don't always travel cleanly. When a company secures a patent in one jurisdiction only to face fresh objections at home, the result is a fascinating collision of legal systems, prior art battles, and the ever-controversial question of what counts as a method of medical treatment. The dispute between Aethlon Medical, Inc. and the Controller General of Patents, Designs, decided on 21 March 2024, is a vivid reminder that international patent wins can create unexpected complications in domestic prosecution.

Aethlon Medical, Inc., the appellant in this matter, found itself in a familiar but uncomfortable position: defending the scope of its patent application before the Controller General of Patents, Designs. The application had already been the subject of intense prosecution in another major jurisdiction — the European Patent Office (EPO) — where Aethlon ultimately accepted limitations to its claims. Those limitations, designed to overcome objections in Europe, became the foundation for an auxiliary request filed in the Indian proceedings. In other words, Aethlon asked the domestic authority to consider a narrowed version of its claims, hoping that what worked in Europe would also satisfy the requirements at home. The stage was thus set for a fresh round of legal friction, this time centered on two recurring flashpoints in patent law: the relevance of prior art and whether the claimed invention falls within the excluded category of methods of treatment.

On one side, Aethlon Medical argued that the amended claims — shaped by the limitations it had accepted at the EPO — should be accepted as a valid compromise. The company effectively contended that the narrowing of its claims addressed the substantive concerns raised during prosecution and that the resulting subject matter deserved protection. On the other side, the Controller General of Patents, Designs scrutinized the amended claims through the lens of two critical legal filters. First, the question of prior art: did the narrowed claims still represent a genuine inventive step over what was already known in the field? Second, the question of patent eligibility: did the application, even as amended, describe a method of treatment of a human or animal body — a category that is typically excluded from patentability? These two issues formed the core of the legal friction, with each side staking out positions on whether the amendments were sufficient to clear both hurdles.

As of the date of the proceedings — 21 March 2024 — the matter remains pending. The court addressed the issues of prior art and method-of-treatment exclusion, but a final determination on the fate of Aethlon's auxiliary request had not yet been issued at the time of this record. The case therefore stands as an open chapter, with the outcome to be decided based on how the tribunal weighs the amended claims against the twin tests of novelty/inventive step and patentable subject matter.

For founders and IP professionals, this case carries a clear strategic lesson: accepting limitations in one jurisdiction is not a guaranteed passport to protection in another. Each patent office applies its own standards for prior art and exclusions such as methods of medical treatment, and what flies in Europe may still face turbulence elsewhere. When pursuing patents internationally, companies should treat each jurisdiction as an independent legal battleground, tailor their claim amendments to local law rather than transplanting foreign compromises wholesale, and anticipate that the same prior art or the same method-of-treatment objection can reappear in a new forum with renewed force.